Environmental

FEMY’s disclosed R&D intensity supports product development, but peers in regulated healthcare often show similar spending, limiting environmental differentiation.

No material emissions, energy, or waste disclosures were provided, so its environmental positioning versus peers remains difficult to verify and likely average.

The absence of reported environmental initiatives reduces evidence of proactive resource management, whereas better-disclosed peers can demonstrate clearer sustainability oversight.

Available metrics do not indicate heavy industrial footprint, which avoids a structural environmental disadvantage relative to manufacturing-intensive peers.

Social

High R&D-to-revenue suggests continued investment in medically relevant innovation, which can support patient-oriented outcomes relative to less research-intensive peers.

Stock-based compensation is elevated, which may aid talent retention in a competitive biotech labor market, though peers often use similar incentives.

No workforce, safety, diversity, or product-access disclosures were provided, limiting evidence that FEMY outperforms peers on core social metrics.

As a small healthcare issuer, FEMY likely faces lower direct community and supply-chain social complexity than larger diversified peers, but this is not substantiated by filings here.

Governance

Debt-to-equity is above zero, but net debt to EBITDA is negative, suggesting leverage is not currently a major governance stress versus more indebted peers.

Stock-based compensation at 23.4% of revenue indicates meaningful dilution risk, which can weaken governance alignment relative to peers with tighter compensation discipline.

No board, audit, ownership, or control-structure disclosures were provided, so governance quality cannot be confirmed against better-governed peers.

The available metrics imply ongoing capital discipline, but the absence of broader governance evidence keeps positioning near the peer median rather than clearly above it.

Overall Score

FEMY appears broadly peer-average on ESG, with some support from innovation intensity and limited leverage concerns, but insufficient disclosure prevents stronger relative positioning.

Score Driver: Limited ESG Disclosure Across Environmental, Social, And Governance Dimensions Is The Main Factor Constraining Relative Peer Assessment.